21st CENTURY ONCOLOGY HOLDINGS,INC. (NYSEMKT:ICC) Files An 8-K Entry into a Material Definitive AgreementItem 1.01 Entry into a Material Definitive Agreement.
As previously disclosed, on December 6, 2016, 21st Century Oncology Holdings, Inc. (“we,” “our,” “us” or the “Company”), 21st Century Oncology, Inc. (“21C”), a subsidiary of the Company, and certain of the Company’s other subsidiaries entered into an Indenture Forbearance Agreement and Credit Agreement Forbearance Agreement (collectively, the “Forbearance Agreements”) with certain of 21C’s noteholders and lenders, respectively. The Forbearance Agreements required, among other things, that 21C enter into a transaction support agreement with its noteholders and lenders (as applicable) no later than December 15, 2016 (the “TSA Deadline”).
Effective as of December 15, 2016, we entered into amendments to the Forbearance Agreements (the “Amendments”) to, among other things, amend the TSA Deadline to January 4, 2017. The Amendments also require us to furnish certain operating and financial data and analysis to the parties to the Forbearance Agreements by the deadlines specified therein.